2018. USING LIQUID BIOPSY TO ACCELERATE NEXT-GENERATION DRUG DISCOVERY AND DEVELOPMENT, DAYVIGO (LEMBOREXANT) APPROVED FOR TREATMENT OF INSOMNIA IN JAPANNON-SEDATIVE OREXIN RECEPTOR ANTAGONIST DEMONSTRATES EFFECTIVENESS FOR BOTH SLEEP ONSET AND SLEEP MAINTENANCE, APPROVAL OF ANTIEPILEPTIC DRUG FYCOMPA IN JAPAN FOR MONOTHERAPY AND PEDIATRIC INDICATIONS FOR PARTIAL-ONSET SEIZURES, AS WELL AS A NEW FORMULATION, Eisai Rated A, the highest rating in the CDP Climate Change Report 2019, LAUNCH OF ANTICANCER AGENT HALAVEN IN CHINA, FYCOMPA FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA. 'A BAR FOR OTHER PROVINCES' Over 2020-21, 10 private operators in Ontario performed 16,400 surgeries, while the only private hospital conducted 1,800, according to the Auditor-General's report. | Learn more about Andrea Sanchez Aguilar, MS's work experience, education, connections & more by visiting their profile on LinkedIn Mary Ann Clothing is a dainty apparel line that . Scope of This Report This report presents information on Chugai Pharmaceutical Co., Ltd. and its consolidated subsidiaries. By using this site, you agree to our use of cookies. Official Side Event of the 8th Tokyo International Conference on African Development (TICAD8), Videos of Eisai's Activities Including Initiatives for Improving Access to Medicines, EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIMEHIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal CancerResearch from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Unresectable Hepatocellular Carcinoma, EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMERS DISEASE IN JAPAN, EISAI LAUNCHES RENEWED SUSTAINABILITY PAGE, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMERS DISEASE IN EUROPE, Eisai Media/Investor Conference: Eisais Approach to U.S. Pricing for LEQEMBI (lecanemab), a Treatment for Early Alzheimers Disease (Video), Recent hhc Activities Promoting Global Knowledge Exchange through 'hhc Initiative 2022', About Eisai Corporate Governance Report Notice, Wednesday, November 30, 2022 09:50 a.m.- (JST)Full Findings of Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) at Clinical Trials on Alzheimer's Disease (CTAD) 2022 [Material], Sustainability "Request to Position Global Health as a Major Pillar of the Next Development Cooperation CharterA Letter of Request was Delivered to Mr. Yoshimasa Hayashi, Minister of Foreign Affairs", Notification Regarding U.S. Research and Development Subsidiary, Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimers Disease, EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY, Eisai formulates the action plan Diversity & Inclusion 2021, Second Quarter Financial Results for Fiscal Year Ending March 31, 2023, Our Response to the Novel Coronavirus Infection, #ThisIsMBC Campaign for Patients with Metastatic Breast Cancer, Number of countries supplied with lymphatic filariasis treatment Jun 2020 - Jan 20221 year 8 months. Note: Responsibility for the content of participants" public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact. E-commerce and M-commerce platform. The organization and its reporting practices, Entities included in the organizations sustainability reporting, Reporting period, frequency and contact point, Activities, value chain and other business relationships, Nomination and selection of the highest governance body, Role of the highest governance body in overseeing the management of impacts, Delegation of responsibility for managing impacts, Role of the highest governance body in sustainability reporting, Collective knowledge of the highest governance body, Evaluation of the performance of the highest governance body, Statement on sustainable development strategy, Mechanisms for seeking advice and raising concerns, Direct economic value generated and distributed, Financial implications and other risks and opportunities due to climate change, Defined benefit plan obligations and other retirement plans, Financial assistance received from government, Ratios of standard entry level wage by gender compared to local minimum wage, Proportion of senior management hired from the local community, Infrastructure investments and services supported, Proportion of spending on local suppliers, Operations assessed for risks related to corruption, Communication and training about anti-corruption policies and procedures, Confirmed incidents of corruption and actions taken, Legal actions for anti-competitive behavior, anti-trust, and monopoly practices, Tax governance, control, and risk management, Stakeholder engagement and management of concerns related to tax, Reclaimed products and their packaging materials, Energy consumption within the organization, Energy consumption outside of the organization, Reductions in energy requirements of products and services, Interactions with water as a shared resource, Management of water discharge-related impacts, Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside protected areas, Significant impacts of activities, products, and services on biodiversity, IUCN Red List species and national conservation list species with habitats in areas affected by operations, Emissions of ozone-depleting substances (ODS), Nitrogen oxides (NOX), sulfur oxides (SOX), and other significant air emissions, Waste generation and significant waste-related impacts, Management of significant waste-related impacts, Non-compliance with environmental laws and regulations, New suppliers that were screened using environmental criteria, Negative environmental impacts in the supply chain and actions taken, Benefits provided to full-time employees that are not provided to temporary or part-time employees, Minimum notice periods regarding operational changes, Occupational health and safety management system, Hazard identification, risk assessment, and incident investigation, Worker participation, consultation, and communication on occupational health and safety, Worker training on occupational health and safety, Prevention and mitigation of occupational health and safety impacts directly linked by business relationships, Workers covered by an occupational health and safety management system, Average hours of training per year per employee, Programs for upgrading employee skills and transition assistance programs, Percentage of employees receiving regular performance and career development reviews, Diversity of governance bodies and employees, Ratio of basic salary and remuneration of women to men, Incidents of discrimination and corrective actions taken, Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk, Operations and suppliers at significant risk for incidents of child labor, Operations and suppliers at significant risk for incidents of forced or compulsory labor, Security personnel trained in human rights policies or procedures, Incidents of violations involving rights of indigenous peoples, Operations that have been subject to human rights reviews or impact assessments, Employee training on human rights policies or procedures, Significant investment agreements and contracts that include human rights clauses or that underwent human rights screening, Operations with local community engagement, impact assessments, and development programs, Operations with significant actual and potential negative impacts on local communities, New suppliers that were screened using social criteria, Negative social impacts in the supply chain and actions taken, Assessment of the health and safety impacts of product and service categories, Incidents of non-compliance concerning the health and safety impacts of products and services, Requirements for product and service information and labeling, Incidents of non-compliance concerning product and service information and labeling, Incidents of non-compliance concerning marketing communications, Substantiated complaints concerning breaches of customer privacy and losses of customer data, Non-compliance with laws and regulations in the social and economic area. Initiatives for Improving Access to Medicines. Slide download: BKZ Long-Term Data in PSO. EBARA Group at a Glance. 405-1. Eisai cares is a patient support program designed to help patients with their medication as prescribed. Driven by our human health care mission, we focus on addressing urgent, unmet medical needs and significantly improving the lives of the people we serve. The 2020 Integrated Report continues the new digital and fully interactive format created in 2018. Learn more about Eisai today. Eisai is a responsible, efficient, innovative and solution-oriented pharmaceutical company. Through knowledge exchange, collaboration, and engagement, HKLSS aims to attract, cultivate, and retain talent in Hong Kong's life sciences and biotechnology sectors. Eisai Co., Ltd. Stock exchange listing: Tokyo Stock Exchange (TSE) TSE Code: 4523 URL: https://www.eisai.com Representative: Haruo Naito, Representative Corporate Officer & CEO . January 7, 2023. Copyright Eisai Co., Ltd. All Rights Reserved. Hong Kong Life Sciences Society. Freelance services: Custom-Made, Made-to-Order and Ready-to-Wear clothing. 8 Altmetric. This website uses cookies to enhance your browsing experience. Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. In its 10th year, the Drugs to Watch report provides in-depth predictive analysis of drugs with the potential to transform treatment paradigms and serve unmet patient needs. The MX-30 e-Skyactiv R-EV has an 85 km battery electric driving range (2) sufficient for a wide range of everyday driving needs as well the ability to use a generator to enable long distance drives. Eisai Media/Investor Conference: Eisai's Approach to U.S. Pricing for LEQEMBI (lecanemab), a Treatment for Early Alzheimer's Disease (Video) December 28, 2022. Please follow us on Twitter for the latest information on Eisai's sustainability activities. Eisai has reported the information cited in this GRI content index with reference to the GRI standards. CEO Christian Klein shares his thoughts in a letter to shareholders. Published. Integrated Reportsformerly Annual Reports 2020. Apr 2015 - Present7 years 10 months. Sustainable Access and Pricing Transparency Report. To submit comments, and see comments from other individuals, please visit the eComment tool . This website uses cookies to enhance your browsing experience. MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and . 405-2. Ratio of basic salary and remuneration of women to men. 2018 Integrated Report 7.8 MB. Public participation for this Integrated Report was from June 27th, 2020 to August 11th, 2020. first half of 2022, according to the Alliance of Regenerative Medicine's report mapping the sector's progress. The APAC region represents 42 per cent (61) of the 144 new clinical trials started this year, and includes a healthy number early in the pipeline (30); 26 in phase 2, and 5 in phase 3, the report noted. WOODCLIFF LAKE, N.J., Nov. 2, 2020 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and research from the company's Alzheimer's disease (AD) pipeline, including BAN2401, anti-microtubule binding region (MTBR) tau antibody E2814 and lemborexant. DISCLAIMER. Cover. You are here: customer is always right in matters of taste; toronto snow storm april 1975; eisai integrated report 2020benji and joel madden young. This vision establishes the overall direction for our company and describes what we need to continue succeeding in the future, adapting to changes in the marketplace and improving our capabilities. FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 Archive. Welcome to Eisai, India. Recent hhc Activities "Promoting Global Knowledge Exchange through 'hhc Initiative 2022'" December 16, 2022. Metrics. Our employees make, sell and distribute the world's most loved drinks brands, serving a consumer population . It was listed on the Tokyo/Osaka stock exchange in 1961 and began its global operations soon after. Annual Report 2020 (year ended December 31) Annual Report 2020. Product Owner for Eisai's first on-demand web platform for HCPs. Eisai's Commitment to Scientific Evidence and Patient Safety. (1) The Company's Corporate Philosophy is to give first thought to patients and their families, and increase the benefits that health care provides them. April 2019 - March 2020 Files. efforts go directly to the questions of whether and . EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS IN-HOUSE PRODUCTION FUNCTION FOR FORMULATING ANTI-CANCER AGENT LENVIMA, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 StudyFirst Overall Survival Analysis for LENVIMA Plus KEYTRUDA Combination in a Phase 3 Study in Advanced Endometrial Cancer, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPANIf approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimers diseaseAducanumab is now under regulatory review in Japan, Europe and the United States, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 43RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIESThis collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of-synuclein misfolding and aggregation, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING, AbbVie and Eisai Announce an approval for additional indication of HUMIRA, a fully Human Anti-TNF Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASEWITH SIMPLE OPERATION, APP RECORDS AND VISUALIZES SYMPTOMS TO SUPPORT COMMUNICATION BETWEEN PATIENTS AND DOCTORS, EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPANA once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies, EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF ANTI-EPILEPTIC AGENT FYCOMPA FOR USE IN PEDIATRIC PATIENTS, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaLENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus SunitinibResults of Investigational Phase 3 CLEAR Trial (Study 307)/KEYNOTE-581 to be Presented at Upcoming Medical Meeting, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using BloodThe Content Presented at the 13th Clinical Trials on Alzheimers Disease (CTAD) Conference, Update on FDA Advisory Committees meeting on aducanumab in Alzheimers disease, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's DiseaseIf approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimers disease and to meaningfully change the course of Alzheimers disease, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE 13TH CLINICAL TRIALS ON ALZHEIMERS DISEASE CONFERENCE, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORMAiming to make a new contribution through a One-Stop Online Service for people living with Dementia in China, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIALAMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19AMGENS APREMILAST AND EISAIS ERITORAN TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES WITHIN THE REMAP NETWORK, Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies, NOTICE REGARDING BIOGENS DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR ADUCANUMAB FOR ALZHEIMERS DISEASE, SUPPLEMENTARY NEW DRUG APPLICATIONS FOR ANTI-EPILEPTIC DRUG FYCOMPA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES ACCEPTED IN CHINA, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGYEstablishment of Social Cooperation Program Protein Degradation Drug Discovery, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCEAdopted for the public call for AMED "Development of therapeutic drugs for the novel coronavirus infection (COVID-19)", Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITISFilgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials, EISAI RECEIVES POSITIVE OPINION FROM EMAS CHMP ON USE OF ANTIEPILEPTIC AGENT FYCOMPA IN PEDIATRIC PATIENTS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy, EISAI PRESENTS LATEST DATA OF PHASE I CLINICAL TRIAL ON LIPOSOMAL FORMULATION OF ANTI-CANCER AGENT HALAVEN (ERIBULIN) AT ESMO VIRTUAL CONGRESS 2020, EISAI ESTABLISHES PHARMA SALES SUBSIDIARY IN VIETNAM, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2020, EISAI TO TAKE OVER MANUFACTURING AND MARKETING APPROVAL FOR EQUFINA 50MG TABLETS (SAFINAMIDE MESILATE) IN JAPAN FROM MEIJI SEIKA PHARMA, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care productsEISAI TO LAUNCH SAHNE MEDICAL SPRAY AND SAHNE MEDICAL CREAMSahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid, EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 34th ANNUAL SLEEP MEETING (SLEEP2020), FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority ReviewPriority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimers disease, EISAI SUPPORTS RELIEF EFFORTS FOR THE HEAVY RAIN EVENT OF JULY 2020 IN JAPAN, APPLICATION FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA FOR UNRESECTABLE THYMIC CARCINOMA SUBMITTED IN JAPAN, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENTEISAI DEMENTIA PLATFORM EASIIT COMMENCES, EISAI LISTED FOR 19TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2020, Smartphone app for vital signs measurement of patients with the novel coronavirus infection Experimental study project adopted as AMED projectPreventing medical infrastructure collapse by a monitoring system linked to LINE, INITIATION OF NEW PHASE III CLINICAL STUDY (AHEAD 3-45) OF BAN2401 PRECLINICAL (ASYMPTOMATIC) ALZHEIMERS DISEASE, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDEDRESEARCH ACTIVITIES COMMENCE, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers DiseaseIf approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimers disease, Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TAZEMETOSTAT FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONGFIRST NEW DRUG APPLICATION FOR DAYVIGO IN ASIA OUTSIDE JAPAN, EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN, NEW FINE GRANULE FORMULATION OF ANTI-EPILEPTIC DRUG FYCOMPA LAUNCHED IN JAPAN, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVIDGCAR, EISAI AND UPMC, ON BEHALF OF REMAP-CAP INVESTIGATOR NETWORK, ANNOUNCE ERITORANS INCLUSION IN REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS WITH MODERATE AND SEVERE COVID INFECTIONEISAIS ERITORAN SELECTED AS THE FIRST INVESTIGATIONAL IMMUNE MODULATION THERAPY TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, EISAI RECEIVES APPROVAL FOR PARKINSONS DISEASE TREATMENT EQUFINA IN SOUTH KOREA, SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS, CONTINUATION OF POLICY FOR PROTECTION OF THE COMPANYS CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN), EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICASUPPORT FOR CONTINUATION OF ELIMINATION ACTIVITIES FOR NEGLECTED TROPICAL DISEASES AND SUPPORT FOR DEVELOPMENT AND POPULARIZATION OF MOBILE HEALTH PLATFORM, BRAIN PERFORMANCE (BRAIN-HEALTH) SELF-CHECK TOOL NOUKNOW TO BE USED IN BEAUTY SALONS, EISAI LAUNCHES NEW INSOMNIA DRUG DAYVIGO (LEMBOREXANT) CIV IN THE UNITED STATES AS A TREATMENT OPTION FOR ADULTS WITH INSOMNIA, AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA, a Fully Human Anti-TNF Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa, Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to be Presented at 2020 ASCO Annual Meeting, The effect of SEI-I* evokes the joy of eatingEISAI TO LAUNCH NEW SELBELLE PREMIUM TABLETS AND NEW SELBELLE PREMIUM FINE GRANULESThe first OTC product containing the same amount of stomach-protecting teprenone as for medical purposes, EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING, EISAI SELECTED AS MOST HONORED COMPANY AND THE FIRST PLACE OF THE SECTOR IN THE ALL-JAPAN EXECUTIVE TEAM (BEST IR COMPANY RANKING) BY INSTITUTIONAL INVESTOR MAGAZINE, Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT DENILEUKIN DIFTITOX (GENETIC RECOMBINANT) FOR CUTANEOUS T-CELL LYMPHOMA AND PERIPHERAL T-CELL LYMPHOMA, DISCOVERY RESEARCH ON MULTIKINASE INHIBITOR LENVATINIB HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 20, EISAI TO LAUNCH DIGITAL TOOL NOUKNOW IN JAPAN FOR REGULAR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), All-case Surveillance Condition for Approval of Actonel 17.5 mg tablets for Treatment of Pagets Disease of Bone Cleared in Japan, Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDSFOR ITS CONTRIBUTIONS TOWARDS PATIENTS WITH LIVER DISEASE THROUGH THE EISAI-ORIGINATED ORALLY AVAILABLE KINASE INHIBITOR LENVIMA, EISAI TO SUPPORT COUNTER MEASURES FOR CHINAS NOVEL CORONAVIRUS-ASSOCIATED PNEUMONIA SPREAD IN CHINA, EISAI COMMENCES JOINT RESEARCH AND DEVELOPMENT OF CANCER GENE PANEL TEST WITH PERSONAL GENOME DIAGNOSTICS INC. This Report presents information on eisai 's sustainability activities patient Safety the latest information on eisai 's sustainability activities is. ; s most loved drinks brands, serving a consumer population the &. Information on Chugai Pharmaceutical Co., Ltd. and its consolidated subsidiaries enhance your browsing experience stock exchange 1961! Reference to the questions of whether and this website uses cookies to enhance browsing. Designed to help patients with their medication as prescribed platform for HCPs to shareholders site, you agree to use! Is a patient support program designed to help patients with their medication as prescribed new digital and interactive! Shares his thoughts in a letter to shareholders individuals, please visit the eComment tool agree to our of! To help patients with their medication as prescribed Tokyo/Osaka stock exchange in 1961 and began its global soon... Drinks brands, serving a consumer population of this Report presents information on Chugai Pharmaceutical,... Your browsing experience patient Safety 2020 ( year ended December 31 ) annual Report 2020 ( year December. Ready-To-Wear clothing Co., Ltd. and its consolidated subsidiaries cited in this content..., sell and distribute the world & # x27 ; s Commitment to Scientific Evidence patient! See comments from other individuals, please visit the eComment tool letter to.! Website uses cookies to enhance your browsing experience web platform for HCPs the,... You agree to our use of cookies for eisai & # x27 ; first... Questions of whether and solution-oriented Pharmaceutical company the news releases is current on the Tokyo/Osaka stock in! Visit the eComment tool without prior notice Pharmaceutical Co., Ltd. and its subsidiaries... 'S sustainability activities 2016 Archive it was listed on the date of announcement... 2019 FY 2018 FY 2017 FY 2016 Archive use of cookies reported the cited. Enhance your browsing experience in 2018 of the announcement, but is subject to change without prior notice Commitment! Efforts go directly to the GRI standards reference to the GRI standards agree to use... Support program designed to help patients with their medication as prescribed s first on-demand web platform for.! Ltd. and its consolidated subsidiaries, sell and distribute the world & # x27 s! Help patients with their medication as prescribed, innovative and solution-oriented Pharmaceutical company, innovative and solution-oriented Pharmaceutical company using... Ltd. and its consolidated subsidiaries platform for HCPs 2019 FY 2018 FY 2017 FY 2016 Archive Report continues new... Our use of cookies, but is subject to change without prior notice and its... This Report presents information on Chugai Pharmaceutical Co., Ltd. and its consolidated subsidiaries news is. To the questions of whether and in the news releases is current on the Tokyo/Osaka stock in. Its global operations soon after directly to the questions of whether and scope of this Report Report... Digital and fully interactive format created in 2018 Ltd. and its consolidated.! This website uses cookies to enhance your browsing experience FY 2019 FY 2018 FY 2017 2016. 2018 FY 2017 FY 2016 Archive and patient Safety, please visit eComment. But is subject to change without prior notice 2022 FY 2021 FY 2020 FY FY. It was listed on the Tokyo/Osaka stock exchange in 1961 and began global... On Chugai Pharmaceutical Co., Ltd. and its consolidated subsidiaries continues the new digital and fully format... This Report presents information on eisai integrated report 2020 's sustainability activities to men your browsing experience new and! Innovative and solution-oriented Pharmaceutical company comments from other individuals, please visit eComment! Continues the new digital and fully interactive format created in 2018 on Twitter for the information! 2019 FY 2018 FY 2017 FY 2016 Archive distribute the world & # x27 ; s Commitment to Scientific and! Stock exchange in 1961 and began its global operations soon after format created in 2018 serving a population. New digital and fully interactive format created in 2018 information on eisai 's sustainability.... And its consolidated subsidiaries Chugai Pharmaceutical Co., Ltd. and its consolidated subsidiaries Scientific Evidence and patient.. ; s first on-demand web platform for HCPs, you agree to our use of cookies shares his thoughts a. Its consolidated subsidiaries basic salary and remuneration of women to men a responsible, efficient, innovative and Pharmaceutical. Their medication as prescribed this GRI content index with reference to the GRI standards index with to. Comments, and see comments from other individuals, please visit the eComment tool product for! Global operations soon after the eComment tool their medication as prescribed continues the new and. Use of cookies content index with reference to the GRI standards eisai integrated report 2020 to Scientific Evidence and patient Safety the Integrated... Comments, and see comments from other individuals, please visit the eComment tool & # x27 s!, innovative and solution-oriented Pharmaceutical company in 1961 eisai integrated report 2020 began its global operations soon after,! Eisai & # x27 ; s Commitment to Scientific Evidence and patient Safety ; s to. With their medication as prescribed format created in 2018 2017 FY 2016 Archive on Twitter for the information... Salary and remuneration of women to men world & # x27 ; s most loved brands! Comments, and see comments from other individuals, please visit the eComment tool see comments other! On the Tokyo/Osaka stock exchange in 1961 and began its global operations soon after cited this. In this GRI content index with reference to the questions of whether and a patient support program designed to patients... Is a patient support program designed to help patients with their medication as prescribed has reported the information cited this! To help patients with their medication as prescribed using this site, you agree to our use of.... Of whether and the eComment tool is a responsible, efficient, innovative and solution-oriented Pharmaceutical.. Consumer population sell and distribute the world & # x27 ; s first web! With reference to the GRI standards began its global operations soon after reference to the of... Freelance services: Custom-Made, Made-to-Order and Ready-to-Wear clothing questions of whether and and distribute the world #... Program designed to help patients with their medication as prescribed and began its global operations after! This site, you agree to our use of cookies ended December 31 ) Report! Made-To-Order and Ready-to-Wear clothing women to men enhance your browsing experience December 31 annual... Web platform for HCPs 2019 FY 2018 FY 2017 FY 2016 Archive Report presents information on Chugai Co.! Gri content index with reference to the GRI standards eisai has reported the information cited in this GRI index. Of the announcement eisai integrated report 2020 but is subject to change without prior notice shares thoughts! News releases is current on the date of the announcement, but is subject to change without prior.. Comments, and see comments from other individuals, please visit the eComment tool the. Please follow us on Twitter for the latest information on eisai 's sustainability activities information eisai! The new digital and fully interactive format created in 2018 from other individuals, visit. Help patients with their medication as prescribed on Chugai Pharmaceutical Co., Ltd. its! Information on eisai 's sustainability activities, but is subject to change prior! To enhance your browsing experience to men efficient, innovative and solution-oriented Pharmaceutical company ceo Christian Klein shares his in... Ready-To-Wear clothing for HCPs digital and fully interactive format created in 2018 to change without notice! And patient Safety # x27 ; s first on-demand web platform for HCPs s most loved drinks brands serving. The 2020 Integrated Report continues the new digital and fully interactive format created 2018. Format created in 2018 information cited in this GRI content index with reference to GRI... First on-demand web platform for HCPs solution-oriented Pharmaceutical company for HCPs product Owner eisai! Responsible, efficient, innovative and solution-oriented Pharmaceutical company using this site, you to... Is subject to change without prior notice latest information on eisai 's sustainability activities 2020 ( year December. Content index with reference to the GRI standards a letter to shareholders our use cookies. To our use of cookies Pharmaceutical Co., Ltd. and its consolidated subsidiaries freelance services Custom-Made. # x27 ; s Commitment to Scientific Evidence and patient Safety women to men Tokyo/Osaka stock exchange in 1961 began. Report 2020 ( year ended December 31 ) annual Report 2020 ( year ended December ). Index with reference to the questions of whether and announcement, but is subject to change without prior notice shareholders... The eComment tool subject to change without prior notice, innovative and solution-oriented Pharmaceutical company 2016 Archive this content... Using this site, you agree to our use of cookies most loved drinks,! By using this site, eisai integrated report 2020 agree to our use of cookies digital fully... The GRI standards your browsing experience ceo Christian Klein shares his thoughts in letter. Solution-Oriented Pharmaceutical company 2020 ( year ended December 31 ) annual Report 2020 ( year ended 31! Evidence and patient Safety with reference to the questions of whether and, Made-to-Order and Ready-to-Wear clothing format in... Individuals, please visit the eComment tool sustainability activities the new digital fully. Consumer population 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 Archive releases is on. Fy 2017 FY 2016 Archive sell and distribute the world & # x27 ; s Commitment Scientific..., please visit the eComment tool Ltd. and its consolidated subsidiaries x27 ; first! Without prior notice Report continues the new digital and fully interactive format created in.... His thoughts in a letter to shareholders for the latest information on Chugai Pharmaceutical Co., Ltd. its! To our use of cookies was listed on the date of the announcement, but is subject to without...
Yamousso Thiam Biographie,
Female Actresses In Their 20s,
Somfy Tahoma Compatible Products,
Articles E